The United States stock market has recently experienced a surge, with major indices like the Dow Jones and Nasdaq Composite showing significant gains amid optimism over reduced China tariffs and ...

Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) – Wedbush issued their Q1 2026 EPS estimates for shares of Travere Therapeutics in a research report issued on Wednesday, April 16th.

Today, the American Kidney Fund (AKF) announces its 2025 Class of Corporate Members who serve as strategic partners in AKF’s Corporate Membership Program. Corporate Members provide vital support to ...

Shares in Travere Therapeutics have lost more than 40% of their value after the company said that a trial designed to confirm the benefits of its recently approved Filspari drug for rare kidney ...

Travere Therapeutics and partner CSL Vifor could be weeks away from EU approval of sparsentan for IgA nephropathy, after getting a positive opinion on the drug from the EMA’s human medicines ...

Nivalis Therapeutics, Inc. (NASDAQ:NVLS) announced that it has dosed the first patient in a second phase II study on its lead ...

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Travere Therapeutics, Inc. before investing. In this article, we go over a few ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.